Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers
Autore:
Mercer, AJ; Lamb, RJ; Rolan, PE; Gibbens, M; Posner, J;
Indirizzi:
Glaxo Wellcome Res & Dev Ltd, Greenford UB6 0HE, Middx, England Glaxo Wellcome Res & Dev Ltd Greenford Middx England UB6 0HE ddx, England Medeval, Manchester M15 4SH, Lancs, England Medeval Manchester Lancs England M15 4SH nchester M15 4SH, Lancs, England Bios Ltd, Surrey GU19 5ER, England Bios Ltd Surrey England GU19 5ERBios Ltd, Surrey GU19 5ER, England
Titolo Testata:
PSYCHOPHARMACOLOGY
fascicolo: 4, volume: 140, anno: 1998,
pagine: 398 - 404
Fonte:
ISI
Lingua:
ENG
Soggetto:
SUMATRIPTAN; MIGRAINE;
Keywords:
311C90; migraine 5-HTIB/ID agonist; psychometric performance; lorazepam; zolmitriptan;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Mercer, AJ Glaxo Wellcome Res & Dev Ltd, Greenford UB6 0HE, Middx, EnglandGlaxo Wellcome Res & Dev Ltd Greenford Middx England UB6 0HE d
Citazione:
A.J. Mercer et al., "Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers", PSYCHOPHAR, 140(4), 1998, pp. 398-404

Abstract

The novel selective 5-hydroxytryptamine (5-HT)(1B/1D) agonist, zolmitriptan (Zomig, formerly known as 311C90), has shown good efficacy in the acute oral treatment of migraine. Zolmitriptan acts both centrally and peripherally, therefore it is important to assess central nervous system effects. At single doses of 25-50 mg (up to 8 times the likely therapeutic dose), zolmitriptan can cause sedation; therefore, a study was designed to examine the dose-response. A double-blind, randomized, placebo-controlled, six-limb crossover study in 13 healthy volunteers compared the effects of single oral doses of zolmitriptan (5, 10, 15 or 20 mg) and lorazepam (2 mg) on various psychometric tests. Zolmitriptan doses less than 20 mg had no statistically significant effects on choice reaction time, the Stroop test, visual analog scale (VAS) assessments of physical sedation, tranquilization and other types of feelings, the logical reasoning test or the adaptive tracking test. There was a mild transient increase in the subjective assessment on VAS of mental sedation which was dose related and occurred mainly with the highest zolmitriptan dose and were not reflected in objective measures of drug effects. In contrast, lorazepam (used as a positive control) was associated with statistically significant impairment in all tests (except tranquilization) for up to 10 h after dosing. The results demonstrate that therapeutic doses of zolmitriptan are unlikely to cause clinically significant impairment in psychometric performance.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 00:50:09